PCRX Pacira Biosciences Inc.

Pacira BioSciences to Present at the 2020 H.C. Wainwright 22nd Annual Global Investment Conference

Pacira BioSciences to Present at the 2020 H.C. Wainwright 22nd Annual Global Investment Conference

PARSIPPANY, N.J., Sept. 11, 2020 (GLOBE NEWSWIRE) -- (NASDAQ: PCRX) today announced that it will present at the 2020 H.C. Wainwright 22nd Annual Global Investment Conference at 3:30 PM ET on Monday, September 14, 2020. Live audio of the virtual event can be accessed by visiting the “Events” page of the company’s website at . A replay of the webcast will also be available for two weeks following the event.

About Pacira                                                                           

Pacira BioSciences, Inc. (NASDAQ: PCRX) is a leading provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for health care practitioners and their patients. The company’s long-acting local analgesic, EXPAREL® (bupivacaine liposome injectable suspension) was commercially launched in the United States in April 2012. EXPAREL utilizes DepoFoam®, a unique and proprietary product delivery technology that encapsulates drugs without altering their molecular structure, and releases them over a desired period of time.  In April 2019, the company acquired the iovera⁰ system, a handheld cryoanalgesia device used to deliver precise, controlled doses of cold temperature only to targeted nerves. To learn more about Pacira, including the corporate mission to reduce overreliance on opioids, visit .

Company Contact:

Pacira BioSciences, Inc.

Christian Pedetti

(973) 254-4387

EN
11/09/2020

Underlying

PCRXPacira Biosciences Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Pacira Biosciences Inc.

 PRESS RELEASE
Free
PCRX Pacira Bioscien...

Pacira Biosciences Joins PROBE Consortium to Transform Osteoarthritis ...

Pacira Biosciences Joins PROBE Consortium to Transform Osteoarthritis Research and Care --Public-private partnership aims to improve osteoarthritis research, diagnosis and treatment----PROBE will leverage data from over 70 million individuals across multiple OA cohorts and real-world registries-- BRISBANE, Calif., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Pacira Biosciences, Inc. (NASDAQ: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies to transform the lives of patients, today announced it has joined the PROBE (Patient Relevant Osteoarthritis endpoints using B...

December 18, 2025 1 EN
 PRESS RELEASE
Free
PCRX Pacira Bioscien...

Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule...

Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) BRISBANE, Calif., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies to transform the lives of patients, today announced the granting of inducement awards on December 1, 2025 to two new employees under Pacira’s Amended and Restated 2014 Inducement Plan (the “Inducement Plan”) as a material inducement to each employee’s entry into employment with the company. In accordance with Nasdaq Listing Rule 5635(c)(4), ...

December 3, 2025 1 EN
 PRESS RELEASE
Free
PCRX Pacira Bioscien...

Pacira BioSciences Announces Results From 12-Month Pilot Study Demonst...

Pacira BioSciences Announces Results From 12-Month Pilot Study Demonstrating Favorable Safety and Significant Improvements in Pain With iovera° Compared to Radiofrequency Ablation in Chronic Low Back Pain -- New data published in Pain Physician shows significant improvement in functional outcomes with iovera° ---- Fewer iovera° patients required additional spine injections after 180 days ---- No treatment-related adverse events were reported -- BRISBANE, Calif., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX), the industry leader in its commitment to deliver inn...

December 2, 2025 1 EN
 PRESS RELEASE
Free
PCRX Pacira Bioscien...

Pacira BioSciences Files EXPAREL® Patent Infringement Lawsuits Against...

Pacira BioSciences Files EXPAREL® Patent Infringement Lawsuits Against The WhiteOak Group and Qilu Pharmaceutical -- Lawsuit triggers 30-month stay under the Hatch Waxman Act -- BRISBANE, Calif., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced that it has filed a patent infringement lawsuit in the United States District Court for the District of Delaware against The WhiteOak Group, Inc. and Qilu Pharmaceutical (Hainan) Co., ...

November 26, 2025 1 EN
Free Trial
PCRX Pacira Bioscien...

Pacira Biosciences Inc: 1 director

A director at Pacira Biosciences Inc sold 12,060 shares at 22.090USD and the significance rating of the trade was 51/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years ...

PCRX PACIRA BIOSCIENCES INC.
11/14/25 November 14, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch